Periodontal Disease Treatment of a Physically Challenged Population (PDT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Oravital Inc.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
Oravital Inc Identifier:
First received: October 29, 2012
Last updated: October 30, 2012
Last verified: October 2012

Many physically handicapped patients at the dental department, Toronto Rehabilitation Institute(TRI) have considerable gingival inflammation and breath odour because of the inability to effectively handle a toothbrush. These patients have considerable periodontal disease. There is a concern that these pathogens may have a detrimental effect on wound healing in other areas of the body.

Hypothesis: Patients attending the dental department at TRI that are treated with the antibiotic-antifungal rinse containing metronidazole and nystatin will show substantial decrease in periodontal disease as measured by bleeding points and pocket depth when compared to the group that continues to use their regular oral hygiene methods (control group).

Condition Intervention
Periodontal Disease
Drug: metronidazole-nystatin oral rinse

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: The Effect of an Antibiotic-antifungal Rinse on Periodontal Disease

Resource links provided by NLM:

Further study details as provided by Oravital Inc:

Primary Outcome Measures:
  • Evidence of healing of periodontal tissues as shown by a reduction of bleeding [ Time Frame: two weeks ] [ Designated as safety issue: No ]
    Evidence of healing of periodontal tissues is assessed by measuring bleeding points and periodontal pocket depth using a dental probe.

Estimated Enrollment: 20
Study Start Date: November 2012
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Metronidazole-nystatin oral rinse, regular oral hygiene

Metronidazole-nystatin rinse, 3ml, rinse for 30 seconds and spit out two times a day.

Group 2 will brush twice a day

Drug: metronidazole-nystatin oral rinse


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Participants must be between the ages of 18 to 65 years Participants must have at least 6 teeth. Participants must have some indication of gingivitis and periodontal breakdown. -

Exclusion Criteria:

Patients who are taking Warfarin/Coumadin Patients who are allergic to Metronidazole or chlorhexidine. Edentulous patients will be excluded by those who have at least 6 teeth can be a participant


  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01718912

Canada, Ontario
Toronto Rehabilitation Institute, Dental Department Not yet recruiting
Toronto, Ontario, Canada, M5G 2A2
Contact: Robert Schlosser, DDS    416 5973422 ext 3048   
Principal Investigator: Robert Schlosser, DDS         
Sponsors and Collaborators
Oravital Inc
  More Information

No publications provided

Responsible Party: Oravital Inc Identifier: NCT01718912     History of Changes
Other Study ID Numbers: OVTRI, TRI
Study First Received: October 29, 2012
Last Updated: October 30, 2012
Health Authority: Canada: Ethics Review Committee

Keywords provided by Oravital Inc:
periodontal disease
bleeding on probing
periodontal pockets

Additional relevant MeSH terms:
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on March 26, 2015